Cosmetic composition of fluid formed during hatching fish roe

FIELD: cosmetics.

SUBSTANCE: invention refers to cosmetic and pharmaceutical industry and represents a method for producing a cosmetic composition of fluid formed during the hatching of fish roe, including at least the following steps: (a) suspending of fish roe in minimal volume of water; (b) induction of synchronized fast hatching said caviar, preferably so, that hatching is terminated for less than 6 hours for more than 80% of embryos; (c) filtration of liquid, formed at hatching, from step (b) to obtain a composition, note here that said fluid filtration stage, formed at hatching includes a liquid filter formed at hatching, using a filter with pore size of at least 5 mcm and collecting of the filtrate; (d) treating the filtrate from stage (c) by means of ion-exchange chromatography, including: (1) loading of the filtrate to ion-exchange column, preferably on DEAE (diethylaminoethylic) column; (2) washing the column by suitable buffer, preferably buffered by irrigating solution with pH 7–9; (3) elution of column leucolectin polypeptides using first elution buffer or solvent, note here that preferably the first elution buffer comprises buffered flushing solution, additionally contains salt in concentration of 50 to 100 mM; (4) elution from column of remaining polypeptides using second elution buffer or solvent, at that, preferably second elution buffer comprises buffered flushing solution, containing salt in concentration of 500 mM to 2 M; (5) collecting eluate from step (4); (e) replacement of water in the eluate from step (5) on a cosmetically acceptable buffer; (f) filtering the solution obtained at step (e), using a filter with pore size of 0.15–0.30 mcm and collecting the filtrate; and (g) preparation of said cosmetic composition from the filtrate obtained at step (f).

EFFECT: invention provides effective skin moistening and pilling of the stratum corneum.

25 cl, 7 dwg, 1 tbl, 6 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an antiseptic pharmaceutical composition applicable for oral hygiene and treatment of microbial oral diseases, to a method for producing and using it. The composition contains from 0.05 to 0.3 wt % of hydrogen peroxide or its equivalent amount in the form of carbamide peroxide, from 0.001 to 0.03 wt % of eugenol, from 0.001 to 0.01 wt % of camphor, from 0.001 to 0.5 wt % of a salt of zinc or other heavy metals, such as silver, mercury, copper or a mixture thereof; from 1 to 1.2 wt % of sodium fluoride; from 2% to 7 wt % of xylitol, from 0.002 to 0.05 wt % of cetylpyridinium chloride and excipients in an amount sufficient to reduce the composition to 100%. The composition possesses a wide spectrum of action. What is also presented is a method for producing the composition and using it for producing a therapeutic agent effective for odour elimination, suppression and relief of an oral inflammation, dental tartar inhibition; for treating oral diseases; for rinsing and treating orthodontic damages; for preventing oral diseases during orthodontic treatment after oral operations and in the patients using fixed and temporary dentures; for relieving, treating or preventing oral diseases in different categories of patients, such as the patients receiving radiation therapy or chemotherapy, hospital patients and terminally ill patients, patients suffering from eating disorders, endocrine, haematological, cardiovascular and psychosomatic disorders, and besides physically or mentally deprived patients, patients with genetic or inherited changes.

EFFECT: preparing the antiseptic pharmaceutical composition.

22 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetology and describes method of stopping unwanted hair growth on different body parts, characterised by the fact that first mechanical removal of hair with root on selected part of skin is performed with further application on said zone with open follicle ostia of depilatory based on salts of thioglycolic acid, sodium, potassium and calcium hydroxides and following rubbing to provide penetration of depilatory into hair follicle.

EFFECT: invention provides possibility of simultaneous destruction of hair follicle with preparations, allowed in medicine and cosmetology.

FIELD: chemistry.

SUBSTANCE: invention relates to cosmetic industry and provides a composition for depositing on keratin surfaces, which contains composition particles in the form of fused agglomerates having a part containing at least one dye and a part containing at least one transparent and translucent thermoplastic material, where the composition particles contain, based on the weight of all of the powdered composition material, about 10 to 90 parts of the dye part and about 90 to 10 parts of the transparent and translucent thermoplastic material part, and a method of producing the powdered composition material.

EFFECT: invention enables to obtain cosmetic compositions which will have an improved outer appearance on the skin and fewer SKU.

23 cl, 10 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: invention refers to dentistry, namely represents an encapsulated oral care composition and an oral care device. According to the invention, the composition contains: (a) a gelatine capsule; and (b) an oral care composition inside the capsule and containing: (i) a hydrophilic active ingredient, (ii) a hydrophobic structuring ingredient, and (iii) an oil carrier. The hydrophilic active ingredient preferentially represents cetylpyridinium chloride. The hydrophobic structuring ingredient preferentially represents gelated mineral oil.

EFFECT: developing the composition according to the invention solves the problem of cetylpyridinium chloride migration and fish-eye capsule defect.

9 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: claimed invention relates to cosmetic field, namely represents method of colouring or lightening of keratin fibres, which includes stage of mixing without preparation at the moment of application of two compositions (A) and (B) and application of said mixture on said fibres; with said mixture including, at least, 25% of fatty substances relative to the total weight of composition, obtained in mixing two compositions (A)+(B).

EFFECT: method by invention makes it possible to produce intensive and uniform colouring of keratin fibres, with method simultaneously being easy to realise, because mixture in form of oil-reach emulsion does not flow down, but remains on application place, as well as makes it possible to lighten keratin fibres.

19 cl, 3 tbl, 1 ex

Shower gel // 2555358

FIELD: cosmetology.

SUBSTANCE: shower gel comprises lauryl glucoside, sodium carboxylate and lauryl glucoside, coco glucoside, cocon amidopropylbetaine, guar-hydroxypropyltrionium chloride, coco glucoside and glyceryl oleate, ethyl alcohol, a fragrance component, sanguinitrine derived from small-fruited plumepoppy, citric acid and water. The components of the gel are in a certain ratio in wt %.

EFFECT: invention provides high washing and foam-generating capacity with soft action which does not disturb the lipid layer of the skin and has a disinfecting action, without destroying own microflora of human skin.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to liposomal compositions for application in cosmetic industry, including i) from 0.001 to 1 wt % of cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or its salt or solvate, ii) from 0.01 to 20 wt % of one or more lipids; iii) from 60 to 99.99 wt % of one or more physiologically acceptable solvents, as well as to method of their obtaining and application for care and preservation of general condition of skin or hare, for prevention or reduction of wrinkles.

EFFECT: claimed compositions demonstrate favourable properties: improved effectiveness, higher stability, reduced immunogenic reactions in comparison with known properties.

18 cl, 3 dwg, 29 tbl, 18 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to cosmetology and hygiene and provides a foaming detergent composition which contains: a) surfactants consisting of decyl glucoside and coco glucoside, where the decyl glucoside is present in an amount by weight which is 1.8 to 2.2 times the weight of coco glucoside, and b) water, where the amount of decyl glucoside is 10 to 30 wt % of the composition, wherein the composition is free of anionic surfactants.

EFFECT: invention enables to produce a detergent composition having foaming properties in the absence of an anionic surfactant that are equally effective as with a composition with an anionic surfactant.

23 cl, 6 ex

FIELD: cosmetology.

SUBSTANCE: invention is the biological means for cleaning and restoration of skin, comprising pancreatic tissue of pigs or birds, 70% ethyl alcohol, fragrance component, and Ringer's solution, at that the components in the means are in a certain ratio, in wt %.

EFFECT: acceleration of the process of skin regeneration, expanding of range of means having cleaning and skin restoring action.

3 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy.

EFFECT: invention enables providing higher clinical effectiveness in the patients with acne and connective tissue dysplasia.

1 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.

EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.

11 cl, 15 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.

EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.

1 ex

FIELD: medicine.

SUBSTANCE: praziquantel is administered in a single dose of 20 mc/kg for the first day of treatment in the daytime, and withdrawn; on the following day, the conducted therapy is added with introducing Gelmicide, a biologically active food supplement, in a dose of 2 capsules with meals for 21 days; the course is repeated 10 days later in a dose of 2 capsules 2 times a day with meals for 14 days.

EFFECT: reducing the rate of complications and increasing the high dishelminthisation efficacy.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula , suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.

EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.

3 cl, 109 ex, 7 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) : or a salt thereof, wherein R1 and R5 are independently selected from H, OH and alkoxy; R2-R4 and R6-R8 are independently selected from H, OH, F, Cl, Br and I; R9 and R10 are C2-C8 alkenyl; under the condition that at least one of R1, R5 and R7 is OH or alkoxy; at least one of R2-R4, R6 and R8 is F, Cl, Br or I; and R2 and R6 are Cl. The invention also relates to an antibacterial composition and treatment methods.

EFFECT: improved properties.

18 cl, 7 ex, 10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.

EFFECT: invention provides the high level of antibacterial activity and stability.

5 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns treating telangiectasia or related symptoms. To this effect, an involved skin area is coated with a composition containing from approximately 0.4 wt % to approximately 0.6 wt % brimonidine providing its blood serum or plasma concentration, Cmax of approximately 54±28 pg/ml or less and AUC0-24h of approximately 568±277 pg·h/ml or less.

EFFECT: method provides the effective treatment of telangiectasia or related symptoms with no side local and systemic effects.

20 cl, 6 dwg, 6 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for treating acne, rosacea and hyperpigmentation, in the form of a gel which contains anchoic acid, a hydrophobic ingredient, a non-aqueous solvent, an emulsifying agent, a gel-forming polymer, a preserving agent, a pH control agent and additionally methylpyrrolidone with anchoic acid having a particle size of less than 100 mcm, while anchoic acid is related to methylpyrrolidone as 1:0.025 to 1:4.

EFFECT: invention provides easy penetration of anchoic acid through a horny layer and its resolution into the oil grand ducts and between skin cells, providing high concentration of anchoic acid that promotes better antibacterial, keratolytic and de-pigmentation effects.

5 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a compound of Formula


where Y represents a group of formula -(CR9R10)-; X is selected from the group, consisting of -C(=O)-, -OC(=O)-, -NHC(=O)-, -(CR11R12)- and -S(-O)2-; Z represents a group of formula -(CR13R14)q-; R1 is selected from the group, consisting of C1-C12alkyl, optionally substituted with one substituent, selected from naphthyl, indole and biphenyl; C2-C12alkenyl, substituted with a substituent, selected from thienyl, naphthyl and phenyl, with the said phenyl being optionally substituted with 1-2 substituents; selected from halogen, trifluoroalkyl, C1-C6alkyl, methoxy and hydroxy; C3-C6cycloalkyl; C6-C10aryl, optionally substituted with 1-2 substituents, selected from halogen, phenyl, amino, phenoxy, C1-C6alkyl, methoxy, hydroxyl and carboxy; and C4-C9heteroaryl, selected from indole, quinoline, quinoxaline, benzofuranyl, benzothiophene, benzimidazole, benzotriazole, benzodioxin, benzothiasole, pyrazole, furyl and isoxazole, optionally substituted with a substituent, selected from C1-C6alkyl and phenyl; R2 and R3 each is independently selected from the group, consisting of H and C1-C12alkyl; R4a is selected from the group, consisting of H, C1-C12alkyl, optionally substituted with phenyl; C2-C12alkenyl, C3-C6cycloalkyl, C6aryl, C(=O)R15, C(=O)NR15R16, C(=O)OR15, SO2R15 and -C(=NR15)-NR16R17; R4d represents hydrogen or R4a and R4b, taken together with a nitrogen atom, which they are bound to, form an optionally substituted heterocyclic fragment, selected from piperidine, morpholine, pyrrolidine and azetidine, where the substituent is selected from C1-C12alkyl, hydroxy, halogen, carboxy and oxo; each R5a and R5b represents H, or R6, R7 and R8 each is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6-C10aryl, optionally substituted with halogen, or taken together with a carbon atom, which they are bound to, two or more of R6, R7 and R8 form a fragment, selected from the group, consisting of C2-C12alkenyl; C3-C6cycloalkyl, optionally substituted with C1-C6alkyl; C6aryl, optionally substituted with 2 substituents, selected from halogen; each R9 and R10 represents H or C1-C12alkyl, substituted with naphthyl; each R11 and R12 represents H; R13 and R14 represent H, or each R15, R16 and R17 is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6aryl, substituted with one substituent, selected from C1-C6alkyl; and C5-heteroaryl, additionally containing one nitrogen atom, with the said heteroaryl representing pyridyl; q represents an integer number, selected from the group, consisting of 2, 3 and 4; r represents 1; or its pharmaceutically acceptable salt. The invention also relates to particular compounds of 1,4-diazepan-2-one derivatives.

EFFECT: obtaining 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists.

21 cl, 7 tbl, 110 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.

EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.

47 cl, 1 tbl, 54 ex